1. Home
  2. IMUX vs CTOR Comparison

IMUX vs CTOR Comparison

Compare IMUX & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • CTOR
  • Stock Information
  • Founded
  • IMUX 2016
  • CTOR 2021
  • Country
  • IMUX United States
  • CTOR United States
  • Employees
  • IMUX N/A
  • CTOR N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • CTOR
  • Sector
  • IMUX Health Care
  • CTOR
  • Exchange
  • IMUX Nasdaq
  • CTOR NYSE
  • Market Cap
  • IMUX 86.3M
  • CTOR 89.9M
  • IPO Year
  • IMUX N/A
  • CTOR N/A
  • Fundamental
  • Price
  • IMUX $0.95
  • CTOR $1.21
  • Analyst Decision
  • IMUX Strong Buy
  • CTOR Strong Buy
  • Analyst Count
  • IMUX 6
  • CTOR 2
  • Target Price
  • IMUX $12.67
  • CTOR $4.50
  • AVG Volume (30 Days)
  • IMUX 1.0M
  • CTOR 85.3K
  • Earning Date
  • IMUX 02-20-2025
  • CTOR 02-21-2025
  • Dividend Yield
  • IMUX N/A
  • CTOR N/A
  • EPS Growth
  • IMUX N/A
  • CTOR N/A
  • EPS
  • IMUX N/A
  • CTOR N/A
  • Revenue
  • IMUX N/A
  • CTOR N/A
  • Revenue This Year
  • IMUX N/A
  • CTOR N/A
  • Revenue Next Year
  • IMUX N/A
  • CTOR N/A
  • P/E Ratio
  • IMUX N/A
  • CTOR N/A
  • Revenue Growth
  • IMUX N/A
  • CTOR N/A
  • 52 Week Low
  • IMUX $0.92
  • CTOR $0.85
  • 52 Week High
  • IMUX $2.11
  • CTOR $49.00
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 44.34
  • CTOR N/A
  • Support Level
  • IMUX $0.94
  • CTOR N/A
  • Resistance Level
  • IMUX $1.02
  • CTOR N/A
  • Average True Range (ATR)
  • IMUX 0.06
  • CTOR 0.00
  • MACD
  • IMUX 0.00
  • CTOR 0.00
  • Stochastic Oscillator
  • IMUX 44.96
  • CTOR 0.00

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About CTOR CITIUS ONCOLOGY INC

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Share on Social Networks: